Form 4: Travere Therapeutics CEO Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Travere Therapeutics CEO, Eric M. Dube, sold 10,736 shares of common stock at $19.46 per share on January 22, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Eric M. Dube, the CEO of Travere Therapeutics, sold 10,736 shares of the company's common stock on January 22, 2025.
- The sale was executed at a price of $19.46 per share.
- This transaction was conducted under a pre-arranged trading plan, specifically a 10b5-1 plan, adopted on March 15, 2024.
- The sale included shares to cover tax obligations arising from the vesting of restricted stock units.
- Following the transaction, Mr. Dube directly owns 351,239 shares of Travere Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction under a pre-arranged plan, with no indication of positive or negative sentiment. It's a neutral event.
Industry Context
Sales by executives under 10b5-1 plans are common and are generally not viewed as a negative signal, as they are pre-arranged and often for tax or diversification purposes. This is a routine transaction for executives.
Comparison to Industry Standards
- Executive stock sales under 10b5-1 plans are a standard practice across publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
- Similar transactions are regularly reported by executives at companies like BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals.
- The size of the transaction is relatively small compared to the overall holdings of the CEO and is not unusual for executives managing their personal finances.
Stakeholder Impact
- The stock sale may have a minor impact on the share price, but it is unlikely to be significant given the pre-planned nature of the transaction.
- The sale does not impact the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date the 10b5-1 trading plan was adopted. |
| 01/22/2025 | Date of the stock sale transaction. |
| 01/23/2025 | Date the form was signed. |
Keywords
Travere Therapeutics, Eric M. Dube, stock sale, 10b5-1 plan, insider trading, executive compensation, share transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.